|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015.
|
|
2
|
Zaimy MA, Saffarzadeh N, Mohammadi A,
Pourghadamyari H, Izadi P, Sarli A, Moghaddam LK, Paschepari SR,
Azizi H, Torkamandi S and Tavakkoly-Bazzaz J: New methods in the
diagnosis of cancer and gene therapy of cancer based on
nanoparticles. Cancer Gene Ther. 24:233–243. 2017.
|
|
3
|
Vineis P and Wild CP: Global cancer
patterns: Causes and prevention. Lancet. 383:549–557. 2014.
|
|
4
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018.
|
|
5
|
Basuroy R, Bouvier C, Ramage JK, Sissons
M, Kent A and Srirajaskanthan R: Presenting Symptoms and Delay in
Diagnosis of Gastrointestinal and Pancreatic Neuroendocrine
Tumours. Neuroendocrinology. 107:42–49. 2018.
|
|
6
|
Koo MM, Hamilton W, Walter FM, Rubin GP
and Lyratzopoulos G: Symptom signatures and diagnostic timeliness
in cancer patients: A review of current evidence. Neoplasia.
20:165–174. 2018.
|
|
7
|
Smith JS, Lindsay L, Hoots B, Keys J,
Franceschi S, Winer R and Clifford GM: Human papillomavirus type
distribution in invasive cervical cancer and high-grade cervical
lesions: A meta-analysis update. Int J Cancer. 121:621–632.
2007.
|
|
8
|
Yan L, Xu F and Dai CL: Relationship
between epithelial-to-mesenchymal transition and the inflammatory
microenvironment of hepatocellular carcinoma. J Exp Clin Cancer
Res. 37:2032018.
|
|
9
|
Torre LA, Siegel RL, Ward EM and Jemal A:
Global cancer incidence and mortality rates and trends-an update.
Cancer Epidemiol Biomarkers Prev. 25:16–27. 2016.
|
|
10
|
Roy PS and Saikia BJ: Cancer and cure: A
critical analysis. Indian J Cancer. 53:441–442. 2016.
|
|
11
|
Wang JJ, Lei KF and Han F: Tumor
microenvironment: Recent advances in various cancer treatments. Eur
Rev Med Pharmacol Sci. 22:3855–3864. 2018.
|
|
12
|
Okamoto A, Watanabe T, Kamata K, Minaga K
and Kudo M: Recent updates on the relationship between cancer and
autoimmune pancreatitis. Intern Med. 58:1533–1539. 2019.
|
|
13
|
Lujambio A and Lowe SW: The microcosmos of
cancer. Nature. 482:347–355
|
|
14
|
Lee RC, Feinbaum RL and Ambros V: The C.
elegans heterochronic gene lin-4 encodes small RNAs with antisense
complementarity to lin-14. Cell. 75:843–854. 1993.
|
|
15
|
Asli NS, Pitulescu ME and Kessel M:
MicroRNAs in organogenesis and disease. Curr Mol Med. 8:698–710.
2008.
|
|
16
|
Bueno MJ, Perez de Castro I and Malumbres
M: Control of cell proliferation pathways by microRNAs. Cell Cycle.
7:3143–3148. 2008.
|
|
17
|
Lu LF and Liston A: MicroRNA in the immune
system, microRNA as an immune system. Immunology. 127:291–298.
2009.
|
|
18
|
Maatouk D and Harfe B: MicroRNAs in
development. ScientificWorldJournal. 6:1828–1840. 2006.
|
|
19
|
Wang Y and Lee CG: MicroRNA and
cancer-focus on apoptosis. J Cell Mol Med. 13:12–23. 2009.
|
|
20
|
Wu SG, Huang YJ, Bao B, Wu LM, Dong J, Liu
XH, Li ZH, Wang XY, Wang L, Chen BJ and Chen W: miR-508-5p acts as
an anti-oncogene by targeting MESDC1 in hepatocellular carcinoma.
Neoplasma. 64:40–47. 2017.
|
|
21
|
Gao W, Li W, Xiao T, Liu XS and Kaelin WG
Jr: Inactivation of the PBRM1 tumor suppressor gene amplifies the
HIF-response in VHL-/-clear cell renal carcinoma. Proc Natl Acad
Sci USA. 114:1027–1032. 2017.
|
|
22
|
Xiao X, Tang C, Xiao S, Fu C and Yu P:
Enhancement of proliferation and invasion by MicroRNA-590-5p via
targeting PBRM1 in clear cell renal carcinoma cells. Oncol Res.
20:537–544. 2013.
|
|
23
|
Wan HY, Li QQ, Zhang Y, Tian W, Li YN, Liu
M, Li X and Tang H: MiR-124 represses vasculogenic mimicry and cell
motility by targeting amotL1 in cervical cancer cells. Cancer Lett.
355:148–158. 2014.
|
|
24
|
Peng XH, Huang HR, Lu J, Liu X, Zhao FP,
Zhang B, Lin SX, Wang L, Chen HH, Xu X, et al: MiR-124 suppresses
tumor growth and metastasis by targeting Foxq1 in nasopharyngeal
carcinoma. Mol Cancer. 13:1862014.
|
|
25
|
Liang YJ, Wang QY, Zhou CX, Yin QQ, He M,
Yu XT, Cao DX, Chen GQ, He JR and Zhao Q: MiR-124 targets Slug to
regulate epithelial-mesenchymal transition and metastasis of breast
cancer. Carcinogenesis. 34:713–722. 2013.
|
|
26
|
Yan G, Li Y, Zhan L, Sun S, Yuan J, Wang
T, Yin Y, Dai Z, Zhu Y, Jiang Z, et al: Decreased miR-124-3p
promoted breast cancer proliferation and metastasis by targeting
MGAT5. Am J Cancer Res. 9:585–596. 2019.
|
|
27
|
Lagos-Quintana M, Rauhut R, Yalcin A,
Meyer J, Lendeckel W and Tuschl T: Identification of
tissue-specific microRNAs from mouse. Curr Biol. 12:735–739.
2002.
|
|
28
|
Clark AM, Goldstein LD, Tevlin M, Tavare
S, Shaham S and Miska EA: The microRNA miR-124 controls gene
expression in the sensory nervous system of Caenorhabditis elegans.
Nucleic Acids Res. 38:3780–3793. 2010.
|
|
29
|
Zhou Q, Long L, Shi G, Zhang J, Wu T and
Zhou B: Research of the methylation status of miR-124a gene
promoter among rheumatoid arthritis patients. Clin Dev Immunol.
2013:5242042013.
|
|
30
|
Ben Gacem R, Ben Abdelkrim O, Ziadi S, Ben
Dhiab M and Trimeche M: Methylation of miR-124a-1, miR-124a-2, and
miR-124a-3 genes correlates with aggressive and advanced breast
cancer disease. Tumour Biol. 35:4047–4056. 2014.
|
|
31
|
Ando T, Yoshida T, Enomoto S, Asada K,
Tatematsu M, Ichinose M, Sugiyama T and Ushijima T: DNA methylation
of microRNA genes in gastric mucosae of gastric cancer patients:
Its possible involvement in the formation of epigenetic field
defect. Int J Cancer. 124:2367–2374. 2009.
|
|
32
|
Gao C, Shen J, Meng ZX and He XF:
Sevoflurane Inhibits Glioma cells proliferation and metastasis
through miRNA-124-3p/ROCK1 axis. Pathol Oncol Res. 26:947–954.
2020.
|
|
33
|
Zhang TH, Liang LZ, Liu XL, Wu JN, Su K,
Chen JY, Zheng QY, Huang HZ and Liao GQ: [Retracted] Long
non-coding RNA MALAT1 interacts with miR-124 and modulates tongue
cancer growth by targeting JAG1. Oncol Rep. 40:31122018.
|
|
34
|
Wang D, Zhang H, Li M, Frid MG, Flockton
AR, McKeon BA, Yeager ME, Fini MA, Morrell NW, Pullamsetti SS, et
al: MicroRNA-124 controls the proliferative, migratory, and
inflammatory phenotype of pulmonary vascular fibroblasts. Circ Res.
114:67–78. 2014.
|
|
35
|
Furuta M, Kozaki KI, Tanaka S, Arii S,
Imoto I and Inazawa J: miR-124 and miR-203 are epigenetically
silenced tumor-suppressive microRNAs in hepatocellular carcinoma.
Carcinogenesis. 31:766–776. 2010.
|
|
36
|
Cao J, Qiu J, Wang X, Lu Z, Wang D, Feng
H, Li X, Liu Q, Pan H, Han X, et al: Identification of microRNA-124
in regulation of Hepatocellular carcinoma through BIRC3 and the
NF-κB pathway. J Cancer. 9:3006–3015. 2018.
|
|
37
|
Zhou W, He L, Dai Y, Zhang Y, Wang J and
Liu B: MicroRNA-124 inhibits cell proliferation, invasion and
migration by targeting CAV1 in bladder cancer. Exp Ther Med.
16:2811–2820. 2018.
|
|
38
|
Zo RB and Long Z: MiR-124-3p suppresses
bladder cancer by targeting DNA methyltransferase 3B. J Cell
Physiol. 234:464–474. 2018.
|
|
39
|
Zhou L, Xu Z, Ren X, Chen K and Xin S:
MicroRNA-124 (MiR-124) inhibits cell proliferation, metastasis and
invasion in colorectal cancer by downregulating Rho-associated
protein kinase 1(ROCK1). Cell Physiol Biochem. 38:1785–1795.
2016.
|
|
40
|
Taniguchi K, Sugito N, Kumazaki M,
Shinohara H, Yamada N, Nakagawa Y, Ito Y, Otsuki Y, Uno B, Uchiyama
K and Akao Y: MicroRNA-124 inhibits cancer cell growth through
PTB1/PKM1/PKM2 feedback cascade in colorectal cancer. Cancer Lett.
363:17–27. 2015.
|
|
41
|
Yuan L, Li S, Zhou Q, Wang D, Zou D, Shu J
and Huang Y: MiR-124 inhibits invasion and induces apoptosis of
ovarian cancer cells by targeting programmed cell death 6. Oncol
Lett. 14:7311–7317. 2017.
|
|
42
|
Shi XB, Xue L, Ma AH, Tepper CG,
Gandour-Edwards R, Kung HJ and deVere White RW: Tumor suppressive
miR-124 targets androgen receptor and inhibits proliferation of
prostate cancer cells. Oncogene. 32:4130–4138. 2013.
|
|
43
|
Gan H, Liu H, Zhang H, Li Y, Xu X, Xu X
and Xu J: SHh-Gli1 signaling pathway promotes cell survival by
mediating baculoviral IAP repeat-containing 3 (BIRC3) gene in
pancreatic cancer cells. Tumour Biol. 37:9943–9950. 2016.
|
|
44
|
Smolewski P and Robak T: Inhibitors of
apoptosis proteins (IAPs) as potential molecular targets for
therapy of hematological malignancies. Curr Mol Med. 11:633–649.
2011.
|
|
45
|
Frazzi R: BIRC3 and BIRC5: Multi-faceted
inhibitors in cancer. Cell Biosci. 11:82021.
|
|
46
|
Jia X, Wang X, Guo X, Ji J, Lou G, Zhao J,
Zhou W, Guo M, Zhang M, Li C, et al: MicroRNA-124: An emerging
therapeutic target in cancer. Cancer Med. 8:5638–5650. 2019.
|
|
47
|
Tutar Y: miRNA and cancer; computational
and experimental approaches. Curr Pharm Biotechnol. 15:4292014.
|
|
48
|
Zhang L, Chen X, Liu B and Han J:
MicroRNA-124-3p directly targets PDCD6 to inhibit metastasis in
breast cancer. Oncol Lett. 15:984–990. 2018.
|
|
49
|
Wu Q, Xu L, Wang C, Fan W, Yan H and Li Q:
MicroRNA-124-3p represses cell growth and cell motility by
targeting EphA2 in glioma. Biochem Biophys Res Commun.
503:2436–2442. 2018.
|
|
50
|
Yu B, Jiang K and Zhang J: MicroRNA-124
suppresses growth and aggressiveness of osteosarcoma and inhibits
TGF-beta-mediated AKT/GSK-3beta/SNAIL-1 signaling. Mol Med Rep.
17:6736–6744. 2018.
|
|
51
|
Moghadasi M, Alivand M, Fardi M, Moghadam
KS and Solali S: Emerging molecular functions of microRNA-124:
Cancer pathology and therapeutic implications. Pathol Res Pract.
216:1528272020.
|
|
52
|
Wang P, Zhang LD, Sun MC, Gu WD and Geng
HZ: Over-expression of mir-124 inhibits MMP-9 expression and
decreases invasion of renal cell carcinoma cells. Eur Rev Med
Pharmacol Sci. 22:6308–6314. 2018.
|
|
53
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
|
|
54
|
Hosseinahli N, Aghapour M, Duijf PHG and
Baradaran B: Treating cancer with microRNA replacement therapy: A
literature review. J Cell Physiol. 233:5574–5588. 2018.
|
|
55
|
Nagini S: Breast cancer: Current molecular
therapeutic targets and new players. Anticancer Agents Med Chem.
17:152–163. 2017.
|
|
56
|
Chen WY: Exogenous and endogenous hormones
and breast cancer. Best Pract Res Clin Endocrinol Metab.
22:573–585. 2008.
|
|
57
|
Roodman GD: Mechanisms of bone metastasis.
N Engl J Med. 350:1655–1664. 2004.
|
|
58
|
Scully OJ, Bay BH, Yip G and Yu Y: Breast
cancer metastasis. Cancer Genomics Proteomics. 9:311–320. 2012.
|
|
59
|
Li Z and Kang Y: Emerging therapeutic
targets in metastatic progression: A focus on breast cancer.
Pharmacol Ther. 161:79–96. 2016.
|
|
60
|
Cai WL, Huang WD, Li B, Chen TR, Li ZX,
Zhao CL, Li HY, Wu YM, Yan WJ and Xiao JR: microRNA-124 inhibits
bone metastasis of breast cancer by repressing Interleukin-11. Mol
Cancer. 17:92018.
|
|
61
|
Feng T, Shao F, Wu Q, Zhang X, Xu D, Qian
K, Xie Y, Wang S, Xu N, Wang Y and Qi C: miR-124 downregulation
leads to breast cancer progression via LncRNA-MALAT1 regulation and
CDK4/E2F1 signal activation. Oncotarget. 7:16205–16216. 2016.
|
|
62
|
Yang W, Cui G, Ding M, Yang M and Dai D:
MicroRNA-124-3p.1 promotes cell proliferation through
Axin1-dependent Wnt signaling pathway and predicts a poor prognosis
of triple-negative breast cancer. J Clin Lab Anal.
34:e232662020.
|
|
63
|
Ji H, Sang M, Liu F, Ai N and Geng C:
miR-124 regulates EMT based on ZEB2 target to inhibit invasion and
metastasis in triple-negative breast cancer. Pathol Res Pract.
215:697–704. 2019.
|
|
64
|
Shi P, Chen C, Li X, Wei Z, Liu Z and Liu
Y: MicroRNA-124 suppresses cell proliferation and invasion of
triple negative breast cancer cells by targeting STAT3. Mol Med
Rep. 19:3667–3675. 2019.
|
|
65
|
Sun Y, Li Q, Gui H, Xu DP, Yang YL, Su DF
and Liu X: MicroRNA-124 mediates the cholinergic anti-inflammatory
action through inhibiting the production of pro-inflammatory
cytokines. Cell Res. 23:1270–1283. 2013.
|
|
66
|
Zhang Y, Li X, Zhang J and Liang H:
Natural killer T cell cytotoxic activity in cervical cancer is
facilitated by the LINC00240/microRNA-124-3p/STAT3/MICA axis.
Cancer Lett. 474:63–73. 2020.
|
|
67
|
Liu C, Xing H, Guo C, Yang Z and Wang Y
and Wang Y: MiR-124 reversed the doxorubicin resistance of breast
cancer stem cells through STAT3/HIF-1 signaling pathways. Cell
Cycle. 18:2215–2227. 2019.
|
|
68
|
Yu X, Li Z, Zheng H, Chan MT and Wu WK:
NEAT1: A novel cancer-related long non-coding RNA. Cell Prolif.
50:e123292017.
|
|
69
|
Jiang X, Zhou Y, Sun AJ and Xue JL: NEAT1
contributes to breast cancer progression through modulating miR-448
and ZEB1. J Cell Physiol. 233:8558–5866. 2018.
|
|
70
|
Pang Y, Wu J, Li X, Wang C, Wang M, Liu J
and Yang G: NEAT1/miR-124/STAT3 feedback loop promotes breast
cancer progression. Int J Oncol. 55:745–754. 2019.
|
|
71
|
Shi P, Liu Y, Yang H and Hu B: Breast
cancer derived exosomes promoted angiogenesis of endothelial cells
in microenvironment via circHIPK3/miR-124-3p/MTDH axis. Cell
Signal. 95:1103382022.
|
|
72
|
Wang YF, Yu L, Hu ZL, Fang YF, Shen YY,
Song MF and Chen Y: Regulation of CCL2 by EZH2 affects
tumor-associated macrophages polarization and infiltration in
breast cancer. Cell Death Dis. 13:7482022.
|
|
73
|
Guo Q, Wang H, Duan J, Luo W, Zhao R, Shen
Y, Wang B, Tao S, Sun Y, Ye Q, et al: An alternatively spliced p62
isoform confers resistance to chemotherapy in breast cancer. Cancer
Res. 82:4001–4015. 2022.
|
|
74
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016.
|
|
75
|
Miller KD, Siegel RL, Lin CC, Mariotto AB,
Kramer JL, Rowland JH, Stein KD, Alteri R and Jemal A: Cancer
treatment and survivorship statistics, 2016. CA Cancer J Clin.
66:271–289. 2016.
|
|
76
|
Palmbos PL, Wang L, Yang H, Wang Y,
Leflein J, Ahmet ML, Wilkinson JE, Kumar-Sinha C, Ney GM, Tomlins
SA, et al: ATDC/TRIM29 drives invasive bladder cancer formation
through miRNA-mediated and epigenetic mechanisms. Cancer Res.
75:5155–5166. 2015.
|
|
77
|
Mitin T, Hunt D, Shipley WU, Kaufman DS,
Uzzo R, Wu CL, Buyyounouski MK, Sandler H and Zietman AL:
Transurethral surgery and twice-daily radiation plus
paclitaxel-cisplatin or fluorouracil-cisplatin with selective
bladder preservation and adjuvant chemotherapy for patients with
muscle invasive bladder cancer (RTOG 0233): A randomised
multicentre phase 2 trial. Lancet Oncol. 14:863–872. 2013.
|
|
78
|
Girardi DM, Ghatalia P, Singh P, Iyer G,
Sridhar SS and Apolo AB: Systemic therapy in bladder preservation.
Urol Oncol. 41:39–47. 2023.
|
|
79
|
Ma Y, Hu Q, Luo W, Pratt RN, Glenn ST, Liu
S, Trump DL and Johnson CS: 1α,25(OH)2D3 differentially regulates
miRNA expression in human bladder cancer cells. J Steroid Biochem
Mol Biol. 148:166–171. 2015.
|
|
80
|
Wang S, Wu G, Han Y, Song P, Chen J, Wu Y,
Yang J and Liang P: miR-124 regulates STAT3-mediated cell
proliferation, migration and apoptosis in bladder cancer. Oncol
Lett. 16:5875–5881. 2018.
|
|
81
|
Li T, Kang G, Wang T and Huang H: Tumor
angiogenesis and anti-angiogenic gene therapy for cancer. Oncol
Lett. 16:687–702. 2018.
|
|
82
|
Annese T, Tamma R, Ruggieri S and Ribatti
D: Erythropoietin in tumor angiogenesis. Exp Cell Res. 374:266–273.
2019.
|
|
83
|
Wang X, Wu Q, Xu B, Wang P, Fan W, Cai Y,
Gu X and Meng F: MiR-124 exerts tumor suppressive functions on the
cell proliferation, motility and angiogenesis of bladder cancer by
fine-tuning UHRF1. FEBS J. 282:4376–4388. 2015.
|
|
84
|
Yao Y, Ma J, Xue Y, Wang P, Li Z, Liu J,
Chen L, Xi Z, Teng H, Wang Z, et al: Knockdown of long non-coding
RNA XIST exerts tumor-suppressive functions in human glioblastoma
stem cells by up-regulating miR-152. Cancer Lett. 359:75–86.
2015.
|
|
85
|
Xiong Y, Wang L, Li Y, Chen M, He W and Qi
L: The long non-coding RNA XIST interacted with MiR-124 to modulate
bladder cancer growth, invasion and migration by targeting androgen
receptor (AR). Cell Physiol Biochem. 43:405–418. 2017.
|
|
86
|
Lombard AP and Mudryj M: The emerging role
of the androgen receptor in bladder cancer. Endocr Relat Cancer.
22:R265–R277. 2015.
|
|
87
|
Aguiar Junior S, Oliveira MM, Silva D,
Mello CAL, Calsavara VF and Curado MP: Survival of patients with
colorectal cancer in a cancer center. Arq Gastroenterol.
57:172–177. 2020.
|
|
88
|
Siegel RL, Miller KD, Goding Sauer A,
Fedewa SA, Butterly LF, Anderson JC, Cercek A, Smith RA and Jemal
A: Colorectal cancer statistics, 2020. CA Cancer J Clin.
70:145–164. 2020.
|
|
89
|
Villeger R, Lopes A, Veziant J, Gagniere
J, Barnich N, Billard E, Boucher D and Bonnet M: Microbial markers
in colorectal cancer detection and/or prognosis. World J
Gastroenterol. 24:2327–2347. 2018.
|
|
90
|
Siegel RL, Miller KD, Fedewa SA, Ahnen DJ,
Meester RGS, Barzi A and Jemal A: Colorectal cancer statistics,
2017. CA Cancer J Clin. 67:177–193. 2017.
|
|
91
|
Kass SU, Pruss D and Wolffe AP: How does
DNA methylation repress transcription? Trends Genet. 13:444–449.
1997.
|
|
92
|
Nakao M and Sasaki H: Genomic imprinting:
Significance in development and diseases and the molecular
mechanisms. J Biochem. 120:467–473. 1996.
|
|
93
|
Panning B and Jaenisch R: RNA and the
epigenetic regulation of X chromosome inactivation. Cell.
93:305–308. 1998.
|
|
94
|
Yoder JA, Walsh CP and Bestor TH: Cytosine
methylation and the ecology of intragenomic parasites. Trends
Genet. 13:335–340. 1997.
|
|
95
|
Lujambio A, Ropero S, Ballestar E, Fraga
MF, Cerrato C, Setién F, Casado S, Suarez-Gauthier A,
Sanchez-Cespedes M, Git A, et al: Genetic unmasking of an
epigenetically silenced microRNA in human cancer cells. Cancer Res.
67:1424–1429. 2007.
|
|
96
|
Chen Z, Liu S, Tian L, Wu M, Ai F, Tang W,
Zhao L, Ding J, Zhang L and Tang A: miR-124 and miR-506 inhibit
colorectal cancer progression by targeting DNMT3B and DNMT1.
Oncotarget. 6:38139–38150. 2015.
|
|
97
|
Zhu J, Zhang R, Yang D, Li J, Yan X, Jin
K, Li W, Liu X, Zhao J, Shang W and Yu T: Knockdown of Long
Non-coding RNA XIST inhibited doxorubicin resistance in colorectal
cancer by upregulation of miR-124 and downregulation of SGK1. Cell
Physiol Biochem. 51:113–128. 2018.
|
|
98
|
Zhang Y, Zheng L, Huang J, Gao F, Lin X,
He L, Li D, Li Z, Ding Y and Chen L: MiR-124 Radiosensitizes human
colorectal cancer cells by targeting PRRX1. PLoS One.
9:e939172014.
|
|
99
|
Xie XQ, Wang MJ, Li Y, Lei LP, Wang N, Lv
ZY, Chen KL, Zhou B, Ping J, Zhou ZG and Sun XF: miR-124
intensified oxaliplatin-based chemotherapy by targeting CAPN2 in
colorectal cancer. Mol Ther Oncolytics. 17:320–331. 2020.
|
|
100
|
Si M, Song Y, Wang X, Wang D, Liu X, Qu X,
Song Z and Yu X: CXCL12/CXCR7/β-arrestin1 biased signal promotes
epithelial-to-mesenchymal transition of colorectal cancer by
repressing miRNAs through YAP1 nuclear translocation. Cell Biosci.
12:1712022.
|
|
101
|
Llovet JM, Montal R, Sia D and Finn RS:
Molecular therapies and precision medicine for hepatocellular
carcinoma. Nat Rev Clin Oncol. 15:599–616. 2018.
|
|
102
|
Vaquero J, Guedj N, Claperon A, Nguyen
Ho-Bouldoires TH, Paradis V and Fouassier L: Epithelial-mesenchymal
transition in cholangiocarcinoma: From clinical evidence to
regulatory networks. J Hepatol. 66:424–441. 2017.
|
|
103
|
Wang H, Mao J, Huang Y, Zhang J, Zhong L,
Wu Y, Huang H, Yang J, Wei Y and Tang J: Prognostic roles of
miR-124-3p and its target ANXA7 and their effects on cell migration
and invasion in hepatocellular carcinoma. Int J Clin Exp Pathol.
13:357–370. 2020.
|
|
104
|
Yue X, Cui Y, You Q, Lu Y and Zhang J:
MicroRNA-124 negatively regulates chloride intracellular channel 1
to suppress the migration and invasion of liver cancer cells. Oncol
Rep. 42:1380–1390. 2019.
|
|
105
|
Zheng F, Liao YJ, Cai MY, Liu YH, Liu TH,
Chen SP, Bian XW, Guan XY, Lin MC, Zeng YX, et al: The putative
tumour suppressor microRNA-124 modulates hepatocellular carcinoma
cell aggressiveness by repressing ROCK2 and EZH2. Gut. 61:278–289.
2012.
|
|
106
|
Cao Q, Yu J, Dhanasekaran SM, Kim JH, Mani
RS, Tomlins SA, Mehra R, Laxman B, Cao X, Yu J, et al: Repression
of E-cadherin by the polycomb group protein EZH2 in cancer.
Oncogene. 27:7274–7284. 2008.
|
|
107
|
Yu J, Cao Q, Mehra R, Laxman B, Yu J,
Tomlins SA, Creighton CJ, Dhanasekaran SM, Shen R, Chen G, et al:
Integrative genomics analysis reveals silencing of beta-adrenergic
signaling by polycomb in prostate cancer. Cancer Cell. 12:419–431.
2007.
|
|
108
|
Thiery JP: Epithelial-mesenchymal
transitions in tumour progression. Nat Rev Cancer. 2:442–454.
2002.
|
|
109
|
Chen G, Shi Y, Liu M and Sun J: circHIPK3
regulates cell proliferation and migration by sponging miR-124 and
regulating AQP3 expression in hepatocellular carcinoma. Cell Death
Dis. 9:1752018.
|
|
110
|
Agre P: The aquaporin water channels. Proc
Am Thorac Soc. 3:5–13. 2006.
|
|
111
|
Magni F, Sarto C, Ticozzi D, Soldi M,
Bosso N, Mocarelli P and Kienle MG: Proteomic knowledge of human
aquaporins. Proteomics. 6:5637–5649. 2006.
|
|
112
|
Hu J and Verkman AS: Increased migration
and metastatic potential of tumor cells expressing aquaporin water
channels. FASEB J. 20:1892–1894. 2006.
|
|
113
|
Jablonski EM, Mattocks MA, Sokolov E,
Koniaris LG, Hughes FM Jr, Fausto N, Pierce RH and McKillop IH:
Decreased aquaporin expression leads to increased resistance to
apoptosis in hepatocellular carcinoma. Cancer Lett. 250:36–46.
2007.
|
|
114
|
Chen XF, Li CF, Lu L and Mei ZC:
Expression and clinical significance of aquaglyceroporins in human
hepatocellular carcinoma. Mol Med Rep. 13:5283–5289. 2016.
|
|
115
|
Yu Q, Chen W, Li Y, He J, Wang Y, Yang S
and Zhou J: The novel circular RNA HIPK3 accelerates the
proliferation and invasion of hepatocellular carcinoma cells by
sponging the micro RNA-124 or micro RNA-506/pyruvate dehydrogenase
kinase 2 axis. Bioengineered. 13:4717–4729. 2022.
|
|
116
|
Liang T, Wang Y, Jiao Y, Cong S, Jiang X,
Dong L, Zhang G and Xiao D: LncRNA MALAT1 accelerates cervical
carcinoma proliferation by suppressing miR-124 expression in
cervical tumor cells. J Oncol. 2021:88360782021.
|
|
117
|
Wang Z, Li S and Zhang G: LncRNA DSCAM-AS1
negatively interacts with miR-124 to promote hepatocellular
carcinoma proliferation. Crit Rev Eukaryot Gene Expr. 32:1–8.
2022.
|
|
118
|
Li J, Feng Q, Wei X and Yu Y: MicroRNA-490
regulates lung cancer metastasis by targeting poly r(C)-binding
protein 1. Tumour Biol. 37:15221–15228. 2016.
|
|
119
|
Tabchi S, Kassouf E, Rassy EE, Kourie HR,
Martin J, Campeau MP, Tehfe M and Blais N: Management of stage III
non-small cell lung cancer. Semin Oncol. 44:163–177. 2017.
|
|
120
|
Gridelli C, Rossi A, Carbone DP, Guarize
J, Karachaliou N, Mok T, Petrella F, Spaggiari L and Rosell R:
Non-small-cell lung cancer. Nat Rev Dis Primers. 1:150092015.
|
|
121
|
Ramnath N, Dilling TJ, Harris LJ, Kim AW,
Michaud GC, Balekian AA, Diekemper R, Detterbeck FC and Arenberg
DA: Treatment of stage III non-small cell lung cancer: Diagnosis
and management of lung cancer, 3rd ed: American College of Chest
Physicians evidence-based clinical practice guidelines. Chest.
143(5 Suppl): e314S–e40S. 2013.
|
|
122
|
Kaplan JA, Liu R, Freedman JD, Padera R,
Schwartz J, Colson YL and Grinstaff MW: Prevention of lung cancer
recurrence using cisplatin-loaded superhydrophobic nanofiber
meshes. Biomaterials. 76:273–281. 2016.
|
|
123
|
Deng XF, Jiang L, Liu QX, Zhou D, Hou B,
Cui K, Min JX and Dai JG: Lymph node micrometastases are associated
with disease recurrence and poor survival for early-stage non-small
cell lung cancer patients: A meta-analysis. J Cardiothorac Surg.
11:282016.
|
|
124
|
Yang Q, Wan L, Xiao C, Hu H, Wang L, Zhao
J, Lei Z and Zhang HT: Inhibition of LHX2 by miR-124 suppresses
cellular migration and invasion in non-small cell lung cancer.
Oncol Lett. 14:3429–3436. 2017.
|
|
125
|
Kim BN, Ahn DH, Kang N, Yeo CD, Kim YK,
Lee KY, Kim TJ, Lee SH, Park MS, Yim HW, et al: TGF-β induced EMT
and stemness characteristics are associated with epigenetic
regulation in lung cancer. Sci Rep. 10:105972020.
|
|
126
|
Zu L, Xue Y and Wang J, Fu Y, Wang X, Xiao
G, Hao M, Sun X, Wang Y, Fu G and Wang J: The feedback loop between
miR-124 and TGF-β pathway plays a significant role in non-small
cell lung cancer metastasis. Carcinogenesis. 37:333–343. 2016.
|
|
127
|
Wang P, Chen L, Zhang J, Chen H, Fan J,
Wang K, Luo J, Chen Z, Meng Z and Liu L: Methylation-mediated
silencing of the miR-124 genes facilitates pancreatic cancer
progression and metastasis by targeting Rac1. Oncogene. 33:514–524.
2014.
|
|
128
|
Wilting SM, van Boerdonk RA, Henken FE,
Meijer CJ, Diosdado B, Meijer GA, le Sage C, Agami R, Snijders PJ
and Steenbergen RD: Methylation-mediated silencing and tumour
suppressive function of hsa-miR-124 in cervical cancer. Mol Cancer.
9:1672010.
|
|
129
|
Qi MM, Ge F, Chen XJ, Tang C and Ma J:
MiR-124 changes the sensitivity of lung cancer cells to cisplatin
through targeting STAT3. Eur Rev Med Pharmacol Sci. 23:5242–5250.
2019.
|
|
130
|
Yu H, Chen Y and Jiang P: Circular RNA
HIPK3 exerts oncogenic properties through suppression of miR-124 in
lung cancer. Biochem Biophys Res Commun. 506:455–462. 2018.
|
|
131
|
Wu J, Weng Y, He F, Liang D and Cai L:
LncRNA MALAT-1 competitively regulates miR-124 to promote EMT and
development of non-small-cell lung cancer. Anticancer Drugs.
29:628–636. 2018.
|
|
132
|
Li H, Guo X, Li Q, Ran P, Xiang X, Yuan Y,
Dong T, Zhu B, Wang L, Li F, et al: Long non-coding RNA 1308
promotes cell invasion by regulating the miR-124/ADAM 15 axis in
non-small-cell lung cancer cells. Cancer Manag Res. 10:6599–6609.
2018.
|
|
133
|
Liu Y, Li L and Song XL: Exosomal circPVT1
derived from lung cancer promotes the progression of lung cancer by
targeting miR-124-3p/EZH2 axis and regulating macrophage
polarization. Cell Cycle. 21:514–530. 2022.
|
|
134
|
Kim K, Zang R, Choi SC, Ryu SY and Kim JW:
Current status of gynecological cancer in China. J Gynecol Oncol.
20:72–76. 2009.
|
|
135
|
Heintz AP, Odicino F, Maisonneuve P, Quinn
MA, Benedet JL, Creasman WT, Ngan HY, Pecorelli S and Beller U:
Carcinoma of the ovary. FIGO 26th annual report on the results of
treatment in gynecological cancer. Int J Gynaecol Obstet. 95(Suppl
1): S161–S192. 2006.
|
|
136
|
Stewart C, Ralyea C and Lockwood S:
Ovarian cancer: An integrated review. Semin Oncol Nurs. 35:151–156.
2019.
|
|
137
|
Zaman MS, Maher DM, Khan S, Jaggi M and
Chauhan SC: Current status and implications of microRNAs in ovarian
cancer diagnosis and therapy. J Ovarian Res. 5:442012.
|
|
138
|
Iorio MV, Visone R, Di Leva G, Donati V,
Petrocca F, Casalini P, Taccioli C, Volinia S, Liu CG, Alder H, et
al: MicroRNA signatures in human ovarian cancer. Cancer Res.
67:8699–8707. 2007.
|
|
139
|
Zhang L, Volinia S, Bonome T, Calin GA,
Greshock J, Yang N, Liu CG, Giannakakis A, Alexiou P, Hasegawa K,
et al: Genomic and epigenetic alterations deregulate microRNA
expression in human epithelial ovarian cancer. Proc Natl Acad Sci
USA. 105:7004–7009. 2008.
|
|
140
|
Mezzanzanica D, Bagnoli M, De Cecco L,
Valeri B and Canevari S: Role of microRNAs in ovarian cancer
pathogenesis and potential clinical implications. Int J Biochem
Cell Biol. 42:1262–1272. 2010.
|
|
141
|
Kunej T, Godnic I, Ferdin J, Horvat S,
Dovc P and Calin GA: Epigenetic regulation of microRNAs in cancer:
An integrated review of literature. Mutat Res. 717:77–84. 2011.
|
|
142
|
Zhang H, Wang Q, Zhao Q and Di W: MiR-124
inhibits the migration and invasion of ovarian cancer cells by
targeting SphK1. J Ovarian Res. 6:842013.
|
|
143
|
Deng X, Chen Y, Liu Z and Xu J:
MiR-124-3p.1 sensitizes ovarian cancer cells to mitochondrial
apoptosis induced by carboplatin. Onco Targets Ther. 13:5375–5386.
2020.
|
|
144
|
Chen L and Kong C: LINC00173 regulates
polycystic ovarian syndrome progression by promoting apoptosis and
repressing proliferation in ovarian granulosa cells via the
microRNA-124-3p (miR-124-3p)/jagged canonical Notch ligand 1 (JAG1)
pathway. Bioengineered. 13:10373–10385. 2022.
|
|
145
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics 2020. CA Cancer J Clin. 70:7–30. 2020.
|
|
146
|
Gomella LG, Petrylak DP and Shayegan B:
Current management of advanced and castration resistant prostate
cancer. Can J Urol. 21(2 Suppl 1): S1–S6. 2014.
|
|
147
|
Scher HI, Buchanan G, Gerald W, Butler LM
and Tilley WD: Targeting the androgen receptor: Improving outcomes
for castration-resistant prostate cancer. Endocr Relat Cancer.
11:459–476. 2004.
|
|
148
|
Salinas CA, Tsodikov A, Ishak-Howard M and
Cooney KA: Prostate cancer in young men: An important clinical
entity. Nat Rev Urol. 11:317–323. 2014.
|
|
149
|
Han M, Partin AW, Pound CR, Epstein JI and
Walsh PC: Long-term biochemical disease-free and cancer-specific
survival following anatomic radical retropubic prostatectomy. The
15-year Johns Hopkins experience. Urol Clin North Am. 28:555–565.
2001.
|
|
150
|
Zhang W, Mao YQ, Wang H, Yin WJ, Zhu SX
and Wang WC: MiR-124 suppresses cell motility and adhesion by
targeting Talin 1 in prostate cancer cells. Cancer Cell Int.
15:492015.
|
|
151
|
Shi XB, Ma AH, Xue L, Li M, Nguyen HG,
Yang JC, Tepper CG, Gandour-Edwards R, Evans CP, Kung HJ and deVere
White RW: miR-124 and androgen receptor signaling inhibitors
repress prostate cancer growth by downregulating androgen receptor
splice variants, EZH2, and Src. Cancer Res. 75:5309–5317. 2015.
|
|
152
|
Yan K, Hou L, Liu T, Jiao W, Ma Q, Fang Z,
Zhang S, Song D, Liu J, Gao X and Fan Y: lncRNA OGFRP1 functions as
a ceRNA to promote the progression of prostate cancer by regulating
SARM1 level via miR-124-3p. Aging (Albany NY). 12:8880–8892.
2020.
|
|
153
|
Shield KD, Ferlay J, Jemal A,
Sankaranarayanan R, Chaturvedi AK, Bray F and Soerjomataram I: The
global incidence of lip, oral cavity, and pharyngeal cancers by
subsite in 2012. CA Cancer J Clin. 67:51–64. 2017.
|
|
154
|
Solomon B, Young RJ and Rischin D: Head
and neck squamous cell carcinoma: Genomics and emerging biomarkers
for immunomodulatory cancer treatments. Semin Cancer Biol.
52:228–240. 2018.
|
|
155
|
Alsahafi E, Begg K, Amelio I, Raulf N,
Lucarelli P, Sauter T and Tavassoli M: Clinical update on head and
neck cancer: Molecular biology and ongoing challenges. Cell Death
Dis. 10:5402019.
|
|
156
|
Salazar C, Nagadia R, Pandit P,
Cooper-White J, Banerjee N, Dimitrova N, Coman WB and Punyadeera C:
A novel saliva-based microRNA biomarker panel to detect head and
neck cancers. Cell Oncol (Dordr). 37:331–338. 2014.
|
|
157
|
Yoshizawa JM and Wong DT: Salivary
microRNAs and oral cancer detection. Methods Mol Biol. 936:313–324.
2013.
|
|
158
|
Lopez-Cortes A, Guerrero S, Redal MA,
Alvarado AT and Quinones LA: State of art of cancer
pharmacogenomics in Latin American Populations. Int J Mol Sci.
18:6392017.
|
|
159
|
Salazar-Ruales C, Arguello JV,
Lopez-Cortes A, Cabrera-Andrade A, Garcia-Cardenas JM,
Guevara-Ramirez P, Peralta P, Leone PE and Paz-Y-Miño C: Salivary
MicroRNAs for Early detection of head and neck squamous cell
carcinoma: A case-control study in the high altitude mestizo
Ecuadorian population. Biomed Res Int. 2018:97927302018.
|
|
160
|
Zhao Y, Ling Z, Hao Y, Pang X, Han X,
Califano JA, Shan L and Gu X: MiR-124 acts as a tumor suppressor by
inhibiting the expression of sphingosine kinase 1 and its
downstream signaling in head and neck squamous cell carcinoma.
Oncotarget. 8:25005–25020. 2017.
|
|
161
|
Yang S, Yuan ZJ, Zhu YH, Chen X and Wang
W: lncRNA PVT1 promotes cetuximab resistance of head and neck
squamous cell carcinoma cells by inhibiting miR-124-3p. Head Neck.
43:2712–2723. 2021.
|
|
162
|
Chen W, Yang J, Fang H, Li L and Sun J:
Relevance function of Linc-ROR in the pathogenesis of cancer. Front
Cell Dev Biol. 8:6962020.
|
|
163
|
Zare A, Ahadi A, Larki P, Omrani MD, Zali
MR, Alamdari NM and Ghaedi H: The clinical significance of miR-335,
miR-124, miR-218 and miR-484 downregulation in gastric cancer. Mol
Biol Rep. 45:1587–1595. 2018.
|
|
164
|
Wu Q, Zhong H, Jiao L, Wen Y, Zhou Y, Zhou
J, Lu X, Song X and Ying B: MiR-124-3p inhibits the migration and
invasion of Gastric cancer by targeting ITGB3. Pathol Res Pract.
216:1527622020.
|
|
165
|
Clevers H: Wnt/beta-catenin signaling in
development and disease. Cell. 127:469–480. 2006.
|
|
166
|
Clevers H and Nusse R: Wnt/beta-catenin
signaling and disease. Cell. 149:1192–1205. 2012.
|
|
167
|
Osaki M, Oshimura M and Ito H: PI3K-Akt
pathway: Its functions and alterations in human cancer. Apoptosis.
9:667–676. 2004.
|
|
168
|
Dai J, Qian C, Su M, Chen M and Chen J:
Gastrokine-2 suppresses epithelial mesenchymal transition through
PI3K/AKT/GSK3β signaling in gastric cancer. Tumour Biol.
37:12403–12410. 2016.
|
|
169
|
Slomovitz BM and Coleman RL: The
PI3K/AKT/mTOR pathway as a therapeutic target in endometrial
cancer. Clin Cancer Res. 18:5856–5864. 2012.
|
|
170
|
Kang S, Dong SM, Kim BR, Park MS, Trink B,
Byun HJ and Rho SB: Thioridazine induces apoptosis by targeting the
PI3K/Akt/mTOR pathway in cervical and endometrial cancer cells.
Apoptosis. 17:989–997. 2012.
|
|
171
|
Bader AG, Kang S, Zhao L and Vogt PK:
Oncogenic PI3K deregulates transcription and translation. Nat Rev
Cancer. 5:921–929. 2005.
|
|
172
|
Parsons R: Phosphatidylinositol 3-kinase
inhibitors are a triple threat to ovarian cancer. Clin Cancer Res.
11:7965–7966. 2005.
|
|
173
|
Hoesel B and Schmid JA: The complexity of
NF-kappaB signaling in inflammation and cancer. Mol Cancer.
12:862013.
|
|
174
|
Romagnoli M, Belguise K, Yu Z, Wang X,
Landesman-Bollag E, Seldin DC, Chalbos D, Barillé-Nion S, Jézéquel
P, Seldin ML and Sonenshein GE: Epithelial-to-mesenchymal
transition induced by TGF-β1 is mediated by Blimp-1-dependent
repression of BMP-5. Cancer Res. 72:6268–6278. 2012.
|
|
175
|
Tobar N, Villar V and Santibanez JF:
ROS-NFkappaB mediates TGF-beta1-induced expression of
urokinase-type plasminogen activator, matrix metalloproteinase-9
and cell invasion. Mol Cell Biochem. 340:195–202. 2010.
|
|
176
|
Yu H and Jove R: The STATs of cancer-new
molecular targets come of age. Nat Rev Cancer. 4:97–105. 2004.
|
|
177
|
Rudan I, Sidhu S, Papana A, Meng SJ,
Xin-Wei Y, Wang W, Campbell-Page RM, Demaio AR, Nair H, Sridhar D,
et al: Prevalence of rheumatoid arthritis in low- and middle-income
countries: A systematic review and analysis. J Glob Health.
5:0104092015.
|
|
178
|
Yar Saglam AS, Alp E, Elmazoglu Z and
Menevse S: Treatment with cucurbitacin B alone and in combination
with gefitinib induces cell cycle inhibition and apoptosis via EGFR
and JAK/STAT pathway in human colorectal cancer cell lines. Hum Exp
Toxicol. 35:526–543. 2016.
|
|
179
|
Saravanan S, Islam VI, Babu NP, Pandikumar
P, Thirugnanasambantham K, Chellappandian M, Raj CS, Paulraj MG and
Ignacimuthu S: Swertiamarin attenuates inflammation mediators via
modulating NF-κB/IκB and JAK2/STAT3 transcription factors in
adjuvant induced arthritis. Eur J Pharm Sci. 56:70–86. 2014.
|
|
180
|
Wang Z, Li Y, Kong D, Ahmad A, Banerjee S
and Sarkar FH: Cross-talk between miRNA and Notch signaling
pathways in tumor development and progression. Cancer Lett.
292:141–148. 2010.
|
|
181
|
Kume T: Novel insights into the
differential functions of Notch ligands in vascular formation. J
Angiogenes Res. 1:82009.
|
|
182
|
Lu ML, Zhang Y, Li J, Fu Y, Li WH, Zhao
GF, Li XH, Wei L, Liu GB and Huang H: MicroRNA-124 inhibits
colorectal cancer cell proliferation and suppresses tumor growth by
interacting with PLCB1 and regulating Wnt/β-catenin signaling
pathway. Eur Rev Med Pharmacol Sci. 23:121–136. 2019.
|
|
183
|
Lemieux E, Cagnol S, Beaudry K, Carrier J
and Rivard N: Oncogenic KRAS signalling promotes the Wnt/β-catenin
pathway through LRP6 in colorectal cancer. Oncogene. 34:4914–4927.
2015.
|
|
184
|
Shahmohamadnejad S, Nouri Ghonbalani Z,
Tahbazlahafi B, Panahi G, Meshkani R, Emami Razavi A, Shokri Afra H
and Khalili E: Aberrant methylation of miR-124 upregulates DNMT3B
in colorectal cancer to accelerate invasion and migration. Arch
Physiol Biochem. 128:1503–1509. 2022.
|
|
185
|
Hernandez-Caballero ME, Sierra - Ramirez
JA, Villalobos-Valencia R and Sesena-Mendez E: Potential of
Kalanchoe pinnata as a cancer treatment adjuvant and an
epigenetic regulator. Molecules. 27:64252022.
|
|
186
|
Zeng L, Fagotto F, Zhang T, Hsu W, Vasicek
TJ, Perry WL III, Lee JJ, Tilghman SM, Gumbiner BM and Costantini
F: The mouse Fused locus encodes Axin, an inhibitor of the Wnt
signaling pathway that regulates embryonic axis formation. Cell.
90:181–192. 1997.
|
|
187
|
Duchartre Y, Kim YM and Kahn M: The Wnt
signaling pathway in cancer. Crit Rev Oncol Hematol. 99:141–149.
2016.
|
|
188
|
Lang Q and Ling C: MiR-124 suppresses cell
proliferation in hepatocellular carcinoma by targeting PIK3CA.
Biochem Biophys Res Commun. 426:247–252. 2012.
|
|
189
|
Napetschnig J and Wu H: Molecular basis of
NF-kappaB signaling. Annu Rev Biophys. 42:443–468. 2013.
|
|
190
|
Hinz M, Stilmann M, Arslan SC, Khanna KK,
Dittmar G and Scheidereit C: A cytoplasmic ATM-TRAF6-cIAP1 module
links nuclear DNA damage signaling to ubiquitin-mediated NF-kappaB
activation. Mol Cell. 40:63–74. 2010.
|
|
191
|
Xie C, Zhang LZ, Chen ZL, Zhong WJ, Fang
JH, Zhu Y, Xiao MH, Guo ZW, Zhao N, He X and Zhuang SM: A
hMTR4-PDIA3P1-miR-125/124-TRAF6 regulatory axis and its function in
NF kappa B signaling and chemoresistance. Hepatology. 71:1660–1677.
2020.
|
|
192
|
Lv Y, Chen S, Wu J, Lin R, Zhou L, Chen G,
Chen H and Ke Y: Upregulation of long non-coding RNA OGFRP1
facilitates endometrial cancer by regulating miR-124-3p/SIRT1 axis
and by activating PI3K/AKT/GSK-3β pathway. Artif Cells Nanomed
Biotechnol. 47:2083–2090. 2019.
|
|
193
|
Li Y, Zhang Z, Liu X, Huang T, He W, Shen
Y, Liu X, Hong K and Cao Q: miR-124 functions as a tumor suppressor
in the endometrial carcinoma cell line HEC-1B partly by suppressing
STAT3. Mol Cell Biochem. 388:219–231. 2014.
|
|
194
|
Yuan D, Zhu D, Yin B, Ge H, Zhao Y, Huang
A, Wang X, Cao X, Xia N and Qian H: Expression of lncRNA NEAT1 in
endometriosis and its biological functions in ectopic endometrial
cells as mediated via miR-124-3p. Genes Genomics. 44:527–537.
2022.
|
|
195
|
Hu YZ, Hu ZL, Liao TY, Li Y and Pan YL:
LncRNA SND1-IT1 facilitates TGF-beta1-induced
epithelial-to-mesenchymal transition via miR-124/COL4A1 axis in
gastric cancer. Cell Death Discov. 8:732022.
|
|
196
|
Jiang L, Lin T, Xu C, Hu S, Pan Y and Jin
R: miR-124 interacts with the Notch1 signalling pathway and has
therapeutic potential against gastric cancer. J Cell Mol Med.
20:313–322. 2016.
|
|
197
|
Xiao HJ, Ji Q, Yang L, Li RT, Zhang C and
Hou JM: In vivo and in vitro effects of microRNA-124 on human
gastric cancer by targeting JAG1 through the Notch signaling
pathway. J Cell Biochem. 119:2520–2534. 2018.
|
|
198
|
Zheng YB, Xiao GC, Tong SL, Ding Y, Wang
QS, Li SB and Hao ZN: Paeoniflorin inhibits human gastric carcinoma
cell proliferation through up-regulation of microRNA-124 and
suppression of PI3K/Akt and STAT3 signaling. World J Gastroenterol.
21:7197–7207. 2015.
|
|
199
|
Wu Z, Huang W, Chen B, Bai PD, Wang XG and
Xing JC: Up-regulation of miR-124 inhibits invasion and
proliferation of prostate cancer cells through mediating JAK-STAT3
signaling pathway. Eur Rev Med Pharmacol Sci. 21:2338–2345.
2017.
|
|
200
|
Qin Z and Liu X: miR-124, a potential
therapeutic target in colorectal cancer. Onco Targets Ther.
12:749–751. 2019.
|
|
201
|
Zhou Z, Lv J, Wang J, Yu H, Lu H, Yuan B,
Han J, Zhou R, Zhang X, Yang X, et al: Role of MicroRNA-124 as a
prognostic factor in multiple neoplasms: A meta-analysis. Dis
Markers. 2019:16547802019.
|
|
202
|
Jiao D, Li Z, Zhu M, Wang Y, Wu G and Han
X: LncRNA MALAT1 promotes tumor growth and metastasis by targeting
miR-124/foxq1 in bladder transitional cell carcinoma (BTCC). Am J
Cancer Res. 8:748–760. 2018.
|
|
203
|
Gao XR, Wang HP, Zhang SL, Wang MX and Zhu
ZS: Pri-miR-124 rs531564 polymorphism and colorectal cancer risk.
Sci Rep. 5:148182015.
|
|
204
|
Long HD, Ma YS, Yang HQ, Xue SB, Liu JB,
Yu F, Lv ZW, Li JY, Xie RT, Chang ZY, et al: Reduced hsa-miR-124-3p
levels are associated with the poor survival of patients with
hepatocellular carcinoma. Mol Biol Rep. 45:2615–2623. 2018.
|
|
205
|
Cong C, Wang W, Tian J, Gao T, Zheng W and
Zhou C: Identification of serum miR-124 as a biomarker for
diagnosis and prognosis in osteosarcoma. Cancer Biomark.
21:449–454. 2018.
|
|
206
|
Davis FG and McCarthy BJ: Current
epidemiological trends and surveillance issues in brain tumors.
Expert Rev Anticancer Ther. 1:395–401. 2001.
|
|
207
|
Chen T, Wang XY, Li C and Xu SJ:
Downregulation of microRNA-124 predicts poor prognosis in glioma
patients. Neurol Sci. 36:131–135. 2015.
|
|
208
|
Romero-Lopez MJ, Jimenez-Wences H, Cruz-De
la Rosa MI, Roman-Fernandez IV and Fernandez-Tilapa G: miR-23b-3p,
miR-124-3p and miR-218-5p synergistic or additive effects on
cellular processes that modulate cervical cancer progression? A
molecular balance that needs attention. Int J Mol Sci.
23:135512022.
|
|
209
|
Ruan F, Wang YF and Chai Y: Diagnostic
values of miR-21, miR-124, and M-CSF in patients with early
cervical cancer. Technol Cancer Res Treat.
19:15330338209149832020.
|
|
210
|
Liang F, Zhang H, Qiu Y, Xu Q, Jian K,
Jiang L, Wang F and Lu X: MiR-124-5p inhibits the progression of
gastric cancer by targeting MIEN1. Technol Cancer Res Treat.
19:15330338209791992020.
|
|
211
|
Liu F, Hu H, Zhao J, Zhang Z, Ai X, Tang L
and Xie L: miR-124-3p acts as a potential marker and suppresses
tumor growth in gastric cancer. Biomed Rep. 9:147–155. 2018.
|
|
212
|
Wu DH, Liang H, Lu SN, Wang H, Su ZL,
Zhang L, Ma JQ, Guo M, Tai S and Yu S: miR-124 suppresses
pancreatic ductal adenocarcinoma growth by regulating
monocarboxylate transporter 1-mediated cancer lactate metabolism.
Cell Physiol Biochem. 50:924–935. 2018.
|
|
213
|
Zhang YH, Wang QQ, Li H, Ye T, Gao F and
Liu YC: miR-124 radiosensitizes human esophageal cancer cell TE-1
by targeting CDK4. Genet Mol Res. 15:2016. View Article : Google Scholar
|
|
214
|
Gao C, Xu YJ, Qi L, Bao YF, Zhang L and
Zheng L: CircRNA VIM silence synergizes with sevoflurane to inhibit
immune escape and multiple oncogenic activities of esophageal
cancer by simultaneously regulating miR-124/PD-L1 axis. Cell Biol
Toxicol. 38:825–845. 2022.
|
|
215
|
Hu D, Li M, Su J, Miao K and Qiu X:
Dual-targeting of miR-124-3p and ABCC4 promotes sensitivity to
Adriamycin in breast cancer cells. Genet Test Mol Biomarkers.
23:156–165. 2019.
|
|
216
|
Du J, He Y, Wu W, Li P, Chen Y, Hu Z and
Han Y: Targeting EphA2 with miR-124 mediates Erlotinib resistance
in K-RAS mutated pancreatic cancer. J Pharm Pharmacol. 71:196–205.
2019.
|
|
217
|
Wang L, Wu M and Zhou X: Long non-coding
RNA UCA1 promotes retinoblastoma progression by modulating the
miR-124/c-myc axis. Am J Transl Res. 14:1592–1605. 2022.
|
|
218
|
Qian C and Wang Y, Ji Y, Chen D, Wang C,
Zhang G and Wang Y: Neural stem cell-derived exosomes transfer
miR-124-3p into cells to inhibit glioma growth by targeting FLOT2.
Int J Oncol. 61:1152022.
|
|
219
|
Gupta D, Zickler AM and El Andaloussi S:
Dosing extracellular vesicles. Adv Drug Deliv Rev.
178:1139612021.
|
|
220
|
Lasser C, Eldh M and Lotvall J: Isolation
and characterization of RNA-containing exosomes. J Vis Exp.
9:e30372012.
|
|
221
|
Barile L and Vassalli G: Exosomes: Therapy
delivery tools and biomarkers of diseases. Pharmacol Ther.
174:63–78. 2017.
|
|
222
|
Isaac R, Reis FCG, Ying W and Olefsky JM:
Exosomes as mediators of intercellular crosstalk in metabolism.
Cell Metab. 33:1744–1762. 2021.
|
|
223
|
Groot M and Lee H: Sorting mechanisms for
MicroRNAs into extracellular vesicles and their associated
diseases. Cells. 9:10442020.
|
|
224
|
Shuang O, Zhou J, Cai Z, Liao L, Wang Y,
Wang W and Xu M: EBF1-mediated up-regulation of lncRNA FGD5-AS1
facilitates osteosarcoma progression by regulating miR-124-3p/G3BP2
axis as a ceRNA. J Orthop Surg Res. 17:3322022.
|
|
225
|
Bronisz A, Godlewski J and Chiocca EA:
Extracellular vesicles and MicroRNAs: Their role in tumorigenicity
and therapy for brain tumors. Cell Mol Neurobiol. 36:361–376.
2016.
|
|
226
|
Ma Y, Shen N, Wicha MS and Luo M: The
roles of the Let-7 family of MicroRNAs in the regulation of cancer
stemness. Cells. 10:24152021.
|
|
227
|
Masliah-Planchon J, Garinet S and Pasmant
E: RAS-MAPK pathway epigenetic activation in cancer: miRNAs in
action. Oncotarget. 7:38892–38907. 2016.
|
|
228
|
Kanlikilicer P, Rashed MH, Bayraktar R,
Mitra R, Ivan C, Aslan B, Zhang X, Filant J, Silva AM,
Rodriguez-Aguayo C, et al: Ubiquitous release of Exosomal tumor
suppressor miR-6126 from ovarian cancer cells. Cancer Res.
76:7194–7207. 2016.
|
|
229
|
Yin Y, Liu B, Cao Y, Yao S, Liu Y, Jin G,
Qin Y, Chen Y, Cui K, Zhou L, et al: Colorectal Cancer-derived
small extracellular vesicles promote tumor immune evasion by
upregulating PD-L1 expression in tumor-associated macrophages. Adv
Sci (Weinh). 9:21026202022.
|
|
230
|
Urabe F, Kosaka N, Sawa Y, Yamamoto Y, Ito
K, Yamamoto T, Kimura T, Egawa S and Ochiya T: miR-26a regulates
extracellular vesicle secretion from prostate cancer cells via
targeting SHC4, PFDN4, and CHORDC1. Sci Adv. 6:eaay30512020.
|
|
231
|
Jiang F and Doudna JA: CRISPR-Cas9
Structures and Mechanisms. Annu Rev Biophys. 46:505–529. 2017.
|
|
232
|
Wang SW, Gao C, Zheng YM, Yi L, Lu JC,
Huang XY, Cai JB, Zhang PF, Cui YH and Ke AW: Current applications
and future perspective of CRISPR/Cas9 gene editing in cancer. Mol
Cancer. 21:572022.
|
|
233
|
Horodecka K and Duchler M: CRISPR/Cas9:
Principle, applications, and delivery through extracellular
vesicles. Int J Mol Sci. 22:60722021.
|
|
234
|
Bao A, Burritt DJ, Chen H, Zhou X, Cao D
and Tran LP: The CRISPR/Cas9 system and its applications in crop
genome editing. Crit Rev Biotechnol. 39:321–336. 2019.
|
|
235
|
Chen M, Mao A, Xu M, Weng Q, Mao J and Ji
J: CRISPR-Cas9 for cancer therapy: Opportunities and challenges.
Cancer Lett. 447:48–55. 2019.
|
|
236
|
Li W, Cho MY, Lee S, Jang M, Park J and
Park R: CRISPR-Cas9 mediated CD133 knockout inhibits colon cancer
invasion through reduced epithelial-mesenchymal transition. PLoS
One. 14:e02208602019.
|
|
237
|
Zhou SJ, Deng YL, Liang HF, Jaoude JC and
Liu FY: Hepatitis B virus X protein promotes CREB-mediated
activation of miR-3188 and Notch signaling in hepatocellular
carcinoma. Cell Death Differ. 24:1577–1587. 2017.
|
|
238
|
Liu C, Ding X, Wei C, Pei Y, Meng F, Zhong
Y and Liu Y: LncRNA LNCOC1 is Upregulated in melanoma and serves as
a potential regulatory target of miR-124 to suppress cancer cell
invasion and migration. Clin Cosmet Investig Dermatol. 15:751–762.
2022.
|
|
239
|
Gupta D, Bhattacharjee O, Mandal D, Sen
MK, Dey D, Dasgupta A, Kazi TA, Gupta R, Sinharoy S, Acharya K, et
al: CRISPR-Cas9 system: A new-fangled dawn in gene editing. Life
Sci. 232:1166362019.
|
|
240
|
Huo W, Zhao G, Yin J, Ouyang X, Wang Y,
Yang C, Wang B, Dong P, Wang Z, Watari H, et al: Lentiviral
CRISPR/Cas9 vector mediated miR-21 gene editing inhibits the
epithelial to mesenchymal transition in ovarian cancer cells. J
Cancer. 8:57–64. 2017.
|
|
241
|
Kunej T, Godnic I, Horvat S, Zorc M and
Calin GA: Cross talk between microRNA and coding cancer genes.
Cancer J. 18:223–231. 2012.
|
|
242
|
Hu S, Zang R, Wang Y, Liang Y, Mu J, Zhang
Y and Ma J: Highly expressed microRNA-124 inhibits migration and
promotes apoptosis of esophageal cancer cells by degrading PDCD6. J
BUON. 24:805–812. 2019.
|
|
243
|
Zhao X, He W, Li J, Huang S, Wan X, Luo H
and Wu D: MiRNA-125b inhibits proliferation and migration by
targeting SphK1 in bladder cancer. Am J Transl Res. 7:2346–2354.
2015.
|
|
244
|
Liu Z, Guo S, Sun H, Bai Y, Song Z and Liu
X: Circular RNA CircHIPK3 elevates CCND2 expression and promotes
cell proliferation and invasion through miR-124 in Glioma. Front
Genet. 11:10132020.
|
|
245
|
Sanuki R and Yamamura T: Tumor suppressive
effects of miR-124 and its function in neuronal development. Int J
Mol Sci. 22:59192021.
|
|
246
|
Yong T, Sun A, Henry MD, Meyers S and
Davis JN: Down regulation of CSL activity inhibits cell
proliferation in prostate and breast cancer cells. J Cell Biochem.
112:2340–2351. 2011.
|
|
247
|
Gao Y, Yang M, Wei L, Liang X, Wu F, Huang
Y and Yang T: miR-34a-5p inhibits cell proliferation, migration and
invasion through targeting JAG1/Notch1 pathway in HPV-infected
human epidermal keratinocytes. Pathol Oncol Res. 26:1851–1859.
2020.
|
|
248
|
Cheng Z, Li X, Ye X, Yu R and Deng Y:
Purpurogallin reverses neuronal apoptosis and enhances 'M2'
polarization of microglia under ischemia via mediating the
miR-124-3p/TRAF6/NF-kappaB axis. Neurochem Res. 48:375–392.
2023.
|
|
249
|
Wu Z, Huang W, Chen B, Bai PD, Wang XG and
Xing JC: Up-regulation of miR-124 inhibits invasion and
proliferation of prostate cancer cells through mediating JAK-STAT3
signaling pathway. Eur Rev Med Pharmacol Sci. 24:75462020.
|
|
250
|
Gao S, Yu J, Shan Z, Zuo L, Huang W, Gan L
and Tian H: IncRNA XIST targets miR-124/JAG1 via CeRNA mechanism to
facilitate the migration and proliferation of tongue squamous cell
carcinoma. Clin Lab. 68:2022. View Article : Google Scholar
|
|
251
|
Guo W, Liu GM, Guan JY, Chen YJ, Zhao YZ,
Wang K and Bai O: Epigenetic regulation of cutaneous T-cell
lymphoma is mediated by dysregulated lncRNA MALAT1 through
modulation of tumor microenvironment. Front Oncol.
12:9772662022.
|
|
252
|
Zhang WL, Zhao YN, Shi ZZ, Gu GY, Cong D,
Wei C and Bai YS: HOXA11-AS promotes the migration and invasion of
hepatocellular carcinoma cells by inhibiting miR-124 expression by
binding to EZH2. Hum Cell. 32:504–514. 2019.
|
|
253
|
Ghafouri-Fard S, Shoorei H, Bahroudi Z,
Abak A, Majidpoor J and Taheri M: An update on the role of miR-124
in the pathogenesis of human disorders. Biomed Pharmacother.
135:1111982021.
|
